ERBB2 and breast carcinoma: Therefore, based on results from previous studies combined with our results, we suggest that Gly may have potential as a prognostic biomarker that reflects tumor aggressiveness associated with HER2 overexpression in ER-positive cancers as well as HER2-positive subtype of breast cancer.